Open AccessIdentification of peptides applicable as vaccines for HLA‐A26‐positive cancer patients
Author(s) -
Niu Yamei,
Terasaki Yasunobu,
Komatsu Nobukazu,
Noguchi Masanori,
Shichijo Shigeki,
Itoh Kyogo
Publication year - 2009
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2009.01298.x
Subject(s) - human leukocyte antigen , cytotoxic t cell , prostate cancer , cancer , immunology , peptide , colorectal cancer , medicine , cancer research , biology , antigen , in vitro , biochemistry
One‐fifth of the Japanese population is positive for HLA‐A26, but few peptides are available as potential cancer vaccines for HLA‐A26‐positive cancer patients. The objective of this study was to identify peptide vaccine candidates for HLA‐A26‐positive cancer patients. The HLA‐A*2601‐crossbinding activity of 24 peptides currently under clinical trial as vaccines for HLA‐A2, ‐A24, or HLA‐A3 supertype–positive cancer patients was evaluated by stabilization assay. Three peptides with HLA‐A2‐binding activity could bind the HLA‐A*2601 molecule. These three peptides induced HLA‐A26‐restricted cytotoxic T lymphocytes from HLA‐A*2601‐, ‐A*2602‐, or ‐A*2603‐positive prostate cancer patients against HLA‐A*2601‐ and HLA‐A*2603‐positive cancer cells in CD8‐dependent and peptide‐specific manners. In addition, one peptide with HLA‐A24‐binding activity could bind to HLA‐A*2601 and induced HLA‐A26‐restricted cytotoxic T lymphocytes from HLA‐A*2601‐, ‐A*2602‐, or ‐A*2603‐positive prostate cancer patients against HLA‐A*2603‐positive cancer cells. These results may provide novel information for the development of a peptide‐based cancer vaccine for HLA‐A26‐positive patients.